These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30321080)

  • 1. Adverse cutaneous effects of neratinib.
    Hamid RN; Ahn CS; Huang WW
    J Dermatolog Treat; 2019 Aug; 30(5):487-488. PubMed ID: 30321080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor.
    Sheu J; Hawryluk EB; Litsas G; Thakuria M; LeBoeuf NR
    Clin Breast Cancer; 2015 Feb; 15(1):e77-81. PubMed ID: 25445421
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer.
    Parma J; Pavlick A; Schiff R; Osborne CK; Chang JC; Rimawi M; Trivedi MV
    Pharmacotherapy; 2013 Oct; 33(10):1126-9. PubMed ID: 23744830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neratinib, A Novel HER2-Targeted Tyrosine Kinase Inhibitor.
    Tiwari SR; Mishra P; Abraham J
    Clin Breast Cancer; 2016 Oct; 16(5):344-348. PubMed ID: 27405796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

  • 6. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.
    Tan AR; Steinberg SM; Parr AL; Nguyen D; Yang SX
    Ann Oncol; 2008 Jan; 19(1):185-90. PubMed ID: 17878175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skin Manifestations of Targeted Antineoplastic Therapy.
    Sanmartín O
    Curr Probl Dermatol; 2018; 53():93-104. PubMed ID: 29131041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy.
    Campbell TM; Brown CW
    J Drugs Dermatol; 2008 Dec; 7(12):1161-3. PubMed ID: 19137770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
    Agirgol S; Çaytemel C; Pilanci KN
    Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU.
    Dhillon S
    Clin Drug Investig; 2019 Feb; 39(2):221-229. PubMed ID: 30607817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
    Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Epidermal growth factor receptor inhibitors side effects].
    Guhl G; González-de Arriba A; Daudén E
    Actas Dermosifiliogr; 2006 Jun; 97(5):296-310. PubMed ID: 16956561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor.
    Fernandez-Galar M; España A; López-Picazo JM
    Clin Exp Dermatol; 2004 Mar; 29(2):138-40. PubMed ID: 14987267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors].
    Tjin-A-ton ML; van Montfrans C; Koldenhof JJ; Sigurdsson V; Voest EE; Witteveen PO
    Ned Tijdschr Geneeskd; 2007 Apr; 151(17):945-52. PubMed ID: 17520845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study.
    Lüftner D; Tesch H; Schmidt M; Hartkopf AD; Streicher S; Resch A; Genovese L; Rosé C; Valenti R; Harbeck N
    Eur J Cancer; 2021 Jun; 150():268-277. PubMed ID: 33971386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant.
    Secombe KR; Ball IA; Shirren J; Wignall AD; Keefe DM; Bowen JM
    Breast Cancer; 2021 Jan; 28(1):99-109. PubMed ID: 32683606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe EGFR inhibitor-induced acneiform eruption responding to dapsone.
    Beshay A; Petersen M; Rhoads JLW
    Dermatol Online J; 2021 Jul; 27(7):. PubMed ID: 34391331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J; Cencelj S
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.
    Anforth R; Liu M; Nguyen B; Uribe P; Kefford R; Clements A; Long GV; Fernandez-Peñas P
    Australas J Dermatol; 2014 Nov; 55(4):250-4. PubMed ID: 24313958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review.
    Yuan C; Wang B
    J Cosmet Dermatol; 2023 Aug; 22(8):2150-2157. PubMed ID: 36924348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.